A1 Refereed original research article in a scientific journal

MYC-Induced miR-203b-3p and miR-203a-3p Control Bc1-xL Expression and Paclitaxel Sensitivity in Tumor Cells




AuthorsAakko Sofia, Straume Anne Hege, Birkeland Einar Elvbakken, Chen Ping, Qiao Xi, Lønning Per Eystein, Kallio Marko J.

PublisherELSEVIER SCIENCE INC

Publication year2019

JournalTranslational Oncology

Journal name in sourceTRANSLATIONAL ONCOLOGY

Journal acronymTRANSL ONCOL

Volume12

Issue1

First page 170

Last page179

Number of pages10

ISSN1936-5233

DOIhttps://doi.org/10.1016/j.tranon.2018.10.001

Web address https://www.sciencedirect.com/science/article/pii/S1936523318304820

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/39719649


Abstract
Taxanes are chemotherapeutic agents used in the treatment of solid tumors, particularly of breast, ovarian, and lung origin. However, patients show divergent therapy responses, and the molecular determinants of taxane sensitivity have remained elusive. Especially the signaling pathways that promote death of the taxane-treated cells are poorly characterized. Here we describe a novel part of a signaling route in which c-Myc enhances paclitaxel sensitivity through upregulation of miR-203b-3p and miR-203a-3p; two clustered antiapoptosis protein BcI-xL controlling microRNAs. In vitro, the miR-203b-3p decreases the expression of BcI-xL by direct targeting of the gene's mRNA 3'UTR. Notably, overexpression of the miR-203b-3p changed the fate of paclitaxel-treated breast and ovarian cancer cells from mitotic slippage to cell death. In breast tumors, high expression of the miR-203b-3p and MYC was associated with better therapy response and patient survival. Interestingly, in the breast tumors, MYC expression correlated negatively with BCL2L1 expression but positively with miR-203b-3p and miR-203a-3p. Finally, silencing of MYC suppressed the transcription of both miRNAs in breast tumor cells. Pending further validation, these results may assist in patient stratification for taxane therapy.

Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 13:59